Collaboration Agreements - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended
	Feb. 28, 2023	May 31, 2022	Aug. 31, 2017	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Jan. 14, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Loss from promissory note early redemption				$ 313	$ 0
Contract liabilities, net of current portion				18,669		$ 18,669
Revenue				0	2,000
Contract with customer, liability, revenue recognized				0
Research and development				3,942	3,133
G42 Investments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Shares sold (in shares)		10,386,274
Sale of stock, price per share (in usd per shares)		$ 2.41
Sale of stock, consideration received on transaction, gross		$ 25,000
Sale of stock, consideration received on transaction		12,500
Accounts and financing receivable, after allowance for credit loss		12,500
Proceeds from collection of notes receivable	$ 12,000
Discount rate	3.75%
Loss from promissory note early redemption	$ 300
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sale of stock, consideration received on transaction, gross		25,000
Accounts and financing receivable, after allowance for credit loss				12,500
Proceeds from collection of notes receivable	$ 12,000
Discount rate	3.75%
Loss from promissory note early redemption	$ 300
Collaborative arrangement, contingent consideration		30,000
Collaborate arrangement, contingent consideration transferred, cash		30,000
Contract liabilities, net of current portion				18,700
Discount on note receivable				600
Collaboration revenue recognized				0
Revenue				0
Receivables, fair value disclosure				11,900
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments | Class A Common Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock, value		$ 5,700
Share price (usd per share)		$ 0.55
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | Cogna
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalties receivable, period		10 years
Collaborative Arrangements | JDRF
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum funding percentage of research and development milestones			50.00%
Collaborative Arrangements | JDRF | Phase 2 MRCT | License and Technology Transfer Services of Chemistry and Manufacturing Know-How
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Adjustments to transaction price for performance obligations				0
Collaborative Arrangements | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 2 MRCT
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum contribution amount to clinical trial							$ 3,000
Potential development and regulatory milestone payments							$ 3,000
Unrecognized amount of transaction price allocated to performance obligation					2,000
Collaborative Arrangements | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 2 MRCT | License and Technology Transfer Services of Chemistry and Manufacturing Know-How
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Adjustments to transaction price for performance obligations				$ 0	$ 2,000